A
AKYA
vs
S&P 500
S&P 500
Over the past 12 months, AKYA has underperformed S&P 500, delivering a return of -45% compared to the S&P 500's +14% growth.
Stocks Performance
AKYA vs S&P 500
Performance Gap
AKYA vs S&P 500
Performance By Year
AKYA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Akoya Biosciences Inc
Glance View
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 319 full-time employees. The company went IPO on 2021-04-16. The firm deliveries spatial biology solutions, which is focused on transforming discovery and clinical research. Spatial biology technology enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, enabling advancements in their understanding of disease progression and patient response to therapy. Through its PhenoCycler and PhenoImager platform, reagents, software and services, it offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research. The company provides PhenoImager HT, which is a digital pathology slide scanner featuring MOTiF whole-slide multispectral scanning of up to seven biomarkers with an 80-slide capacity. The company offers contract research services laboratory, which is called as advanced biopharma solutions.
